Detalles de la búsqueda
1.
Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212).
Int J Cancer;
154(5): 863-872, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37840339
2.
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Br J Cancer;
127(5): 836-843, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35637412
3.
FIRE-9 - PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer.
BMC Cancer;
22(1): 359, 2022 Apr 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35366831
4.
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
Int J Cancer;
149(11): 1935-1943, 2021 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34310714
5.
Patients with colorectal cancer and brain metastasis: The relevance of extracranial metastatic patterns predicting time intervals to first occurrence of intracranial metastasis and survival.
Int J Cancer;
148(8): 1919-1927, 2021 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33113215
6.
Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306.
Ann Surg Oncol;
27(7): 2389-2401, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32172334
7.
Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE-3 trial.
Blood;
139(10): 1593-1597, 2022 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34932794
8.
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer.
Anticancer Drugs;
28(7): 717-722, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28582279
9.
Identification of a gene expression signature associated with brain metastasis in colorectal cancer.
Clin Transl Oncol;
2024 Mar 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38558282
10.
Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212).
Clin Cancer Res;
30(7): 1256-1263, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38289994
11.
Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance.
J Cancer Res Clin Oncol;
149(2): 669-682, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36401637
12.
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Eur J Cancer;
178: 37-48, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36399909
13.
Importance of interdisciplinarity in modern oncology: results of a national intergroup survey of the Young Oncologists United (YOU).
J Cancer Res Clin Oncol;
149(12): 10075-10084, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37261525
14.
The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer.
Nat Commun;
14(1): 5391, 2023 09 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37666855
15.
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials.
Eur J Cancer;
190: 112945, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37441940
16.
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial.
Eur J Cancer;
190: 112955, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37454537
17.
Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212).
J Clin Oncol;
41(16): 2975-2987, 2023 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37018649
18.
[Protection against common cold]. / Gesund durch die Erkältungssaison.
MMW Fortschr Med;
159(1): 43-47, 2017 Jan.
Artículo
en Alemán
| MEDLINE | ID: mdl-28097555
19.
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110).
Eur J Cancer;
173: 194-203, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35940054
20.
Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212).
J Clin Oncol;
40(1): 72-82, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34533973